My #1 Pre IPO Trade for 2025 – NAME and TICKER

One tiny company... Could quickly become "the next SpaceX." It plans to go public on the NASDAQ. And today you can buy Pre-IPO shares for less than $4.00. Get urgent details inside this free report...

Ronald Sugar Biography and Net Worth

Director of Amgen

Ronald D. Sugar is the retired Chairman of the Board and Chief Executive Officer of Northrop Grumman Corporation, a global aerospace and defense company, having held these posts from 2003 through 2009.

Dr. Sugar has been a director of Chevron Corporation, a petroleum, exploration, production and refining company, since 2005, serving as the lead director and on the Management Compensation Committee and chairing the Board Nominating and Governance Committee. Dr. Sugar has been a director of Apple Inc., a manufacturer and seller of, among other things, personal computers, mobile communication and media devices, since 2010, chairing the Audit and Finance Committee. Dr. Sugar has been a director of Uber Technologies, Inc., a personal mobility, meal delivery and logistics technology platform, since 2018, serving as the Chair of the board of directors and chairing the Nominating and Governance Committee and serving on the Compensation Committee. Dr. Sugar served as a director of Air Lease Corporation, an aircraft leasing company, from 2010 to May 2020, and chaired its Compensation Committee and served on the Nominating and Corporate Governance Committee. Since 2010, he has been a senior advisor to Ares Management LLC, a privately-held asset manager and registered investment advisor. In 2014, Dr. Sugar joined the Temasek Americas Advisory Panel of Temasek Holdings (Private) Limited, a privately-held investment company based in Singapore. Dr. Sugar is a member of the National Academy of Engineering, trustee of the University of Southern California, member of the UCLA Anderson School of Management Board of Advisors, and director of the Los Angeles Philharmonic Association.

What is Ronald D. Sugar's net worth?: The estimated net worth of Ronald D. Sugar is at least $4.87 million as of May 12th, 2021. Dr. Sugar owns 16,927 shares of Amgen stock worth more than $4,872,775 as of November 21st. This net worth estimate does not reflect any other investments that Dr. Sugar may own. Learn More about Ronald D. Sugar's net worth.
How do I contact Ronald D. Sugar?: The corporate mailing address for Dr. Sugar and other Amgen executives is ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA, 91320. Amgen can also be reached via phone at (805) 447-1000 and via email at [email protected]. Learn More on Ronald D. Sugar's contact information.
Has Ronald D. Sugar been buying or selling shares of Amgen?: Ronald D. Sugar has not been actively trading shares of Amgen within the last three months. Most recently, Ronald D. Sugar sold 1,000 shares of the business's stock in a transaction on Wednesday, May 12th. The shares were sold at an average price of $250.59, for a transaction totalling $250,590.00. Following the completion of the sale, the director now directly owns 16,927 shares of the company's stock, valued at $4,241,736.93. Learn More on Ronald D. Sugar's trading history.
Who are Amgen's active insiders?: Amgen's insider roster includes Robert Bradway (Chairman & Chief Executive Officer), Robert Eckert (Director), Murdo Gordon (EVP), Jonathan Graham (EVP), Peter Griffith (Exec. VP & CFO ), Nancy Grygiel (SVP), Nancy Grygiel (SVP), Ronald Sugar (Director), Ronald Sugar (Director), and R Williams (Director). Learn More on Amgen's active insiders.
Are insiders buying or selling shares of Amgen?: During the last year, insiders at the medical research company sold shares 2 times. They sold a total of 4,213 shares worth more than $1,235,082.41. The most recent insider tranaction occured on May, 3rd when SVP Nancy A Grygiel sold 2,117 shares worth more than $662,811.53. Insiders at Amgen own 0.7% of the company. Learn More about insider trades at Amgen.
Information on this page was last updated on 5/3/2024.

Ronald D. Sugar Insider Trading History at Amgen

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/12/2021	Sell	1,000	$250.59	$250,590.00	16,927
4/14/2021	Sell	1,000	$249.98	$249,980.00	16,927
3/10/2021	Sell	1,000	$231.53	$231,530.00	16,805
2/10/2021	Sell	1,000	$238.40	$238,400.00	16,805
1/13/2021	Sell	1,000	$235.99	$235,990.00	16,805
8/19/2020	Sell	1,000	$241.02	$241,020.00
7/22/2020	Sell	1,000	$259.79	$259,790.00	16,589
6/17/2020	Sell	1,000	$228.54	$228,540.00	16,576
5/20/2020	Sell	1,000	$229.27	$229,270.00	16,482
4/22/2020	Sell	1,000	$233.35	$233,350.00	15,636
10/2/2019	Sell	2,000	$193.58	$387,160.00	16,436
9/4/2019	Sell	2,000	$206.70	$413,400.00	16,336
7/3/2019	Sell	2,000	$187.58	$375,160.00	16,336
6/5/2019	Sell	2,000	$175.68	$351,360.00	16,219
5/1/2019	Sell	2,000	$175.73	$351,460.00	15,092
4/3/2019	Sell	2,000	$193.18	$386,360.00	15,092
3/6/2019	Sell	2,000	$188.88	$377,760.00	14,988
2/7/2019	Sell	2,000	$190.00	$380,000.00	14,988

Ronald D. Sugar Buying and Selling Activity at Amgen

Amgen Company Overview

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Today's Range

Now: $285.50

$284.32

$288.18

50 Day Range

MA: $318.08

$278.76

$337.38

2 Week Range

Now: $285.50

$260.68

$346.85

Volume

126,514 shs

Average Volume

2,460,242 shs

Market Capitalization

$153.46 billion

P/E Ratio

36.56

Dividend Yield

3.21%

Beta

0.6

My #1 Pre IPO Trade for 2025 – NAME and TICKER

From Wyatt Investment Research | Ad

The Next SpaceX Pre-IPO